Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.7.0.1
Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Accrued expenses:    
Professional fees $ 1,748 $ 1,253
Salaries, bonuses and related benefits 2,295 2,846
Accrued Severance 0 53
Ovamed manufacturing rights - short term component 0 900
Research and development 2,914 394
Dr. Falk Pharma milestone 2,852 2,634
Other 2,564 2,002
Total accrued expenses 12,373 10,082
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 5,026 5,014
Total other long-term liabilities $ 5,026 $ 5,014